Event

ISPOR 2025

Date: May 13th-16th, 2025
Location: Montreal, Canada
Booth #607

Discover our sessions at ISPOR 2025

Podium session

Inclusion of health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in reimbursement reviews from the Canadian Agency for Drugs and Technologies in Health (CADTH)

Date: Wednesday, May 14, 2025 
Time: 10:15am – 11:15am ET
Speaker: Nicole Fusco, Cencora

Educational symposia

Bringing us together or pushing us apart: Will JCA, HEMA, and other cross-border collaboration initiatives improve patient access?

Date: Wednesday, May 14, 2025
Time: 3:15pm – 4:15pm ET
Moderator: Erika Wissinger, Cencora
Panelists: Jon Campbell, National Pharmaceutical Council; Michael Drummond, University of York; Eldon Spackman, University of Calgary 

Issue panel

Prescription drug affordability boards (PDABs): are there opportunities for robust and transparent engagement? 

Date: Friday, May 16, 2025 
Time: 8:00am – 9:00am ET
Speaker: Elaine Tate, Cencora

Podium session

Impact of JCA and Project Orbis on the European revenue potential of an oncology product

Date: Friday, May 16, 2025 
Time: 10:00am – 11:00am ET
Speaker: Claudio Valenti, Cencora 

With team across North America, Europe, and Japan, we blend global reach with local expertise

3,000
Consultants worldwide
30+
Global markets covered
235+
Brands represented

Helping biopharma breakthroughs break through

At Cencora, we’re leading the way to a place where your life-changing therapies can soar to impossible heights. Together, let’s create healthier futures for more patients around the globe.  

Innomar Strategies

Ensuring commercialization success in Canada

For Canadian healthcare market access challenges, InnomarConsulting™ provides solutions across the product lifecycle through unparalleled relationships and valued expertise. By partnering with our team, you help ensure the success of your launch, maximize patient access, improve sales performance, and extend brand relevancy. We help existing manufacturers, as well as those new to Canada, to develop and execute effective commercialization strategies, ensuring patients efficiently gain access to the latest advances in healthcare.

Don’t miss our poster presentations during ISPOR 2025

  • An evaluation of PhlexNeuron, an internal, proprietary artificial intelligence (AI) tool for systematic literature review (SLR) screening
  • Analysis of the effect of Trofinetide treatment on the domain and item-level responses of the Rett syndrome behavior questionnaire using data from the LAVENDER trial
  • Broadening the scope of value: Evaluating payer perspectives and insights on ICER’s latest initiatives and tools

  • Cost-effectiveness analyses of Repotrectinib in TKI-naïve patients with ROS1+ advanced non-small cell lung cancer

  • Inclusion of health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in the United States Food and Drug Administration (FDA) labels
  • Leveraging artificial intelligence to streamline study quality assessment in systematic literature reviews 

  • Payer perceptions on creating a national value assessment body in the US

  • Payer perspectives on ICER Evidence Reports: Insights into utility for coverage and formulary decision-making 
  • Staffing resource use: a cost impact model for the utilization and implementation of medications for opioid use disorder within US jails and prisons

  • Utilization and impact of GLP-1s: Patient-reported healthcare resource utilization and costs in patients with type 2 Diabetes

  • Value of multi-indication immunotherapies for the treatment of autoimmune diseases in the United States (US)

Cencora partners with ISPOR to advance HEOR

We are thrilled to announce Cencora's partnership with ISPOR in their new Corporate Partnership Program! This collaboration aligns with our commitment to advancing health economics and outcomes research. Together, we'll drive innovation, enhance global health outcomes, and strengthen the HEOR community. 

Stay informed on health policy news and health technology insights

From legislative and regulatory developments to expert insights, stay up to date on the latest news.

Catch up on our latest insights

Catch up on the latest edition of HTA Quarterly

In this edition, following the implementation of the European Union (EU) Regulation on Health Technology Assessment (HTAR) for medicinal products in January, we review current processes and prepare for upcoming guidance for medical devices. We also discuss the value of early network mapping in systemic literature reviews (SLRs) for health technology assessment (HTA) submissions and spotlight the improved drug pricing environment in Japan, a result of positive changes to the pricing system adopted in April 2024.

Navigating the Canadian reimbursement landscape

Despite perceptions of a universal healthcare system, Canada’s medication reimbursement relies on both public and private payers, impacting market access for new therapies. In this video, Beth Koster, Director, Health Economics & Outcomes Research (HEOR), shares considerations for market access, including the need for early strategic planning and comprehensive evidence collection.

Meet us at ISPOR

Our consultative approach and extensive reach across healthcare give us access to the best insights in the industry- insights we leverage to help commercialization challenges for our partners and patients they serve. Schedule a meeting with our team at ISPOR to learn more.

Cencora.com fournit des traductions automatiques pour faciliter la lecture du site Web dans des langues autres que l’anglais. Pour ces traductions, des efforts raisonnables ont été faits pour fournir une traduction précise, cependant, aucune traduction automatique n’est parfaite et n’est pas destinée à remplacer les traducteurs humains. Ces traductions sont fournies à titre de service aux utilisateurs de Cencora.com et sont fournies « en l’état ». Aucune garantie d’aucune sorte, expresse ou implicite, n’est donnée quant à l’exactitude, la fiabilité ou l’exactitude de l’une ou l’autre de ces traductions effectuées de l’anglais vers une autre langue. Certains contenus (tels que les images, les vidéos, Flash, etc.) peuvent ne pas être traduits avec précision en raison des limitations du logiciel de traduction.

Toute divergence ou différence créée lors de la traduction de ce contenu de l’anglais vers une autre langue n’est pas contraignante et n’a aucun effet juridique pour la conformité, l’application ou toute autre fin. Si des erreurs sont identifiées, veuillez nouscontacter. Si vous avez des questions concernant l’exactitude des informations contenues dans ces traductions, veuillez vous référer à la version anglaise de la page.